In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
|Articles|December 10, 2015
Quintiles Launches Suite of Services to Integrate Asset Development Planning
Advertisement
New offering incorporates clinical, commercial and regulatory insight to improve the probability of an asset’s commercial success
RESEARCH TRIANGLE PARK, N.C. – December 10, 2015 – Quintiles, the world’s largest provider of biopharmaceutical services, today announced the launch of its Integrated Asset Development Plan (IADP) offering. This new suite of services combines development strategy, regulatory strategy, market and patient access and commercial expertise, with in-depth therapeutic knowledge, a facilitated strategic-planning process, data analytics and modeling to deliver an integrated asset-development plan.
IADP brings together cross-functional strategies and operational delivery to enable more informed decisions that speed market access, fulfill regulatory requirements and help optimize commercial potential. Potential assets that could benefit from this new offering include small molecule drugs, biologics, medical devices, combination therapies and novel technologies.
“In today’s increasingly complex healthcare market, a successful asset must meet key value objectives and evidence needs for a variety of stakeholders, including patients, providers, regulators and payers,” said
As part of the IADP offering, Quintiles advises biopharmaceutical companies on considerations for an asset’s value proposition, Target Product Profile (TPP), regulatory plan, and a
“Based on our experience, having a viable, integrated plan for asset development increases the likelihood of success,” said Sax. “When combined with an in-depth understanding of the cross-functional dependencies and operational requirements, it’s a very powerful approach.”
To learn more about Integrated Asset Development Plan, visit
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit
Advertisement
Related to this article
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In this Q&A, Sylviane de Viron of CluePoints and Abigail Dirks, MS, of Tufts CSDD discuss the findings of a collaborative study quantifying the financial value of RBQM, why time savings emerged as the largest driver, and what sponsors struggling to justify adoption now have that they didn't before.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Leads in Trial Design—and Where Humans Still Need To
2
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
3
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
4
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
5